🧾 What This Document Is

This is an 8-K filing, a mandatory report to the SEC when a major event happens at a public company. This specific filing announces a key executive change: the appointment of a new Chief Financial Officer (CFO). It’s a standard, important update for investors and the market.

🏢 What The Company Does

👉 In simple terms, MaxCyte provides the specialized tools and "recipes" that scientists use to engineer living cells into potential medicines. Their core technology is called Flow Electroporation®, which uses electrical pulses to gently open cell membranes so new genetic instructions can be delivered inside. They serve the booming cell and gene therapy industry, helping drug developers create treatments like CAR-T cell therapies for cancer.

👔 The New Finance Chief

The company appointed Parmeet Ahuja as the new CFO, effective March 30, 2026. He takes over from Douglas Swirsky, whose planned departure was announced in November 2025. This is a planned and orderly transition.

🧠 Why This Hire Matters

The CEO, Maher Masoud, highlights that Ahuja has over 20 years of finance leadership experience at a major life sciences company, Agilent Technologies. His background isn't just in accounting; he specifically worked in investor relations and strategic financial planning. This signals that MaxCyte is prioritizing strong Wall Street communication and disciplined financial strategy as it grows.

🔭 Ahuja's Background & Vision

Ahuja most recently served as Vice President, Investor Relations at Agilent. Before that, he held roles in operational finance, audit, and global financial operations. He holds an MBA in Finance from San Jose State University. In his statement, he expressed excitement about MaxCyte’s "transformative" technology and emphasized supporting "disciplined execution" and the company’s "strategic priorities."

🔮 What's Next for MaxCyte

With this hire, MaxCyte is focused on "strengthening our financial foundation" and advancing its strategic goals. The company describes itself as being at a "pivotal moment." For investors, this means watching how the new CFO’s operational and investor-focused experience translates into financial execution and market messaging in the coming quarters.

⚖️ Big Picture: Strengths & Considerations

• 👍 Strength: Hiring a seasoned finance leader from a respected industry giant like Agilent adds credibility and deep operational expertise. His investor relations background is a major plus for managing shareholder expectations.
• 👍 Strength: The transition was pre-announced (in Nov 2025), which avoids sudden disruption and shows good governance.
• ⚠️ Consideration: As with any executive change, there’s a transition period. Investors will watch to ensure continuity in financial strategy and reporting.

🧠 The Analogy

Think of MaxCyte as a company that builds specialized kitchen appliances for chefs (scientists) creating new molecular gastronomy dishes (cell therapies). Hiring Parmeet Ahuja as CFO is like bringing in a seasoned restaurant CFO who not only knows the books but also knows exactly how to talk to investors about the promise of a new tasting menu and how to manage the costs of a busy kitchen. He’s there to turn the innovative recipes into a sustainable, profitable business.

📇 Key Contacts & People

New CFO: Parmeet Ahuja (effective March 30, 2026) Outgoing CFO: Douglas Swirsky CEO: Maher Masoud Investor Relations Contact: David Deuchler, CFA (Gilmartin Group) - [email protected] Media Contact: Kristen White (Oak Street Communications) - [email protected] | +1 415-608-6060

🧩 Final Takeaway

MaxCyte is strategically strengthening its financial leadership with a seasoned veteran from a top life sciences firm, signaling a focus on operational discipline and clear investor communication as it advances its cell-engineering platform. This is a planned, positive step for the company's next growth phase.